By decreasing the levels of FoxP3 and Treg, increasing the cytotoxicity of NK and CD8+T cells, and increasing the production of proinflammatory cytokines, HDAC inhibitors are conducive to reducing tumor formation and boosting an efficient immune response against cancer cells (102, 103). Here, HDAC9 is linked to neoplasm.